Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acrivon TherapeuticsACRV -0.29%35 Net Debt Paydown Yield % is 1.36% as of Aug. 13, 2026, which is 325% above its 10-year median of 0.32. GuruFocus rates ACRV with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 1,152 Biotechnology companies, Acrivon Therapeutics ranks better than 77.08% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Acrivon Therapeutics's Net Debt Paydown Yield % was 1.36%.
Acrivon Therapeutics (NAS:ACRV) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Acrivon Therapeutics Net Debt Paydown Yield % Related Terms
Acrivon Therapeutics Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Acrivon Therapeutics's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acrivon Therapeutics Net Debt Paydown Yield % Chart
ACRV vs SPRO, BSEM, XBIT: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Acrivon Therapeutics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrivon Therapeutics Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrivon Therapeutics's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Acrivon Therapeutics's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 1.36% mean?
Acrivon Therapeutics (ACRV) has a Net Debt Paydown Yield % of 1.36% as of Aug. 13, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Acrivon Therapeutics and its competitors. This is 325% above median its historical median of 0.32. Over the past decade, Acrivon Therapeutics' Net Debt Paydown Yield % has ranged from 0.17 to 2.20. According to the industry distribution chart, Acrivon Therapeutics ranks #264 out of 1152 companies in the Biotechnology industry, placing it in the top 22.9%.
Is Acrivon Therapeutics' Net Debt Paydown Yield % too high?
Acrivon Therapeutics' current Net Debt Paydown Yield % of 1.36% is 325% above median its 10-year median of 0.32. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 2.20. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. Acrivon Therapeutics' value of 1.36% is 4433.3% above this industry median. Based on the distribution chart, Acrivon Therapeutics ranks #264 out of 1152 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Acrivon Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Acrivon Therapeutics' Net Debt Paydown Yield % compare to SPRO and BSEM?
According to the Biotechnology industry distribution chart, Acrivon Therapeutics ranks #264 out of 1152 companies for Net Debt Paydown Yield %. This places Acrivon Therapeutics in the top 23% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.03. Acrivon Therapeutics' value of 1.36% is 4433.3% above this benchmark. Historically, Acrivon Therapeutics' own Net Debt Paydown Yield % has ranged from 0.17 to 2.20 over the past decade. While the company's 10-year median is 0.32 vs. the industry median of 0.03, Acrivon Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,152 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acrivon Therapeutics's current Net Debt Paydown Yield % of 1.36% is 4433.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Acrivon Therapeutics and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acrivon Therapeutics's current Net Debt Paydown Yield % is 1.36%, which is 325% above median its own 10-year median of 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrivon Therapeutics stock overvalued right now?
Acrivon Therapeutics (ACRV) has a current Net Debt Paydown Yield % of 1.36%. The current Net Debt Paydown Yield % is 1.36%, which is 325% above median its 10-year median of 0.32 and 4433.3% above the Biotechnology industry median of 0.03. Acrivon Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Acrivon Therapeutics (ACRV), the current Net Debt Paydown Yield % is 1.36% as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
35GF Score
Get the complete analysis for ACRV
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACRV has been successfully added to your 
